Breaking News, Collaborations & Alliances

Moffitt Cancer Center Partners with Cryoport

Will bring CRYOGENE’s biorepository services to Speros in Pasco County, FL.

Moffitt Cancer Center, recognized as a comprehensive cancer center by the National Cancer Institute, along with its wholly owned subsidiary, Speros FL—a 775-acre global innovation life sciences campus—and Cryoport Inc., a leader in life sciences supply chain solutions, have formed a strategic partnership, which will bring CRYOGENE’s biorepository services to Speros in Pasco County, Florida.

Cryoport’s CRYOGENE business unit is a leading biorepository for the life sciences industry that is focused on the secure storage of biological specimens and associated services.

“Our goal is to make Speros the cell and gene therapy capital of the world,” said Patrick Hwu, M.D., president and CEO of Moffitt. “With the addition of CRYOGENE, we will accelerate discovery by igniting collaborations and partnerships across disciplines to bring new therapies to patients faster and save more lives.”

“Having CRYOGENE’s facility with a seasoned team located directly on the Speros campus and at Moffitt’s research facility provides top-level research and biotech companies with the critical tools and infrastructure to immediately operate more effectively,” said Marshall Griswold, CEO of CRYOGENE.

The addition of CRYOGENE’s biostorage facility will lay the foundation for Moffitt’s Speros campus as a global epicenter for patient treatment and research in cell and gene therapies, immunotherapies, radiopharmaceuticals, proton therapies and other expanding technologies and treatment pathways. This facility will be included in the initial phase of the development of Speros and is located adjacent to Moffitt’s 250,000-square-foot Discovery & Innovation Center for research.

Biorepositories play a crucial role in the development and storage of cell and gene therapies. CRYOGENE’s optimized storage techniques and strict quality control will enable reliable and scalable production and preservation of cells that will accelerate advancements in adoptive cell therapies. This is key to decentralizing manufacturing, reducing the turnaround time and bringing lifesaving treatments to patients more quickly.

The facility will enhance collaboration across Moffitt’s expanding health system while also supporting emerging blood sciences and organ and tissue biobanking protocols. The biorepository will provide streamlined access to critical research and clinical activities, along with essential capabilities for distributing research and treatment materials.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters